RxDoctor Payments DataLook up a doctor →

John Horan, DO

Family Medicine · Warwick, RINPI 1679567531

Payments from drug & device makers

$8,787in general payments, 2019–2025

Across 560 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Johnson & Johnson$870
  • Pfizer$861
  • Boehringer Ingelheim$548
  • GSK$454
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,74199%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,787 in reported general payments places this provider in the 90th percentile of 222 family medicine providers in Rhode Island.

See all family medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$40,832
Medicare patients
195
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$122,332
JardianceEmpagliflozin43$42,450
OzempicSemaglutide25$33,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,766
JanuviaSitagliptin Phosphate27$30,036
XareltoRivaroxaban40$27,292
CreonLipase/Protease/Amylase19$21,435
Spiriva RespimatTiotropium Bromide36$18,469
Bevespi AerosphereGlycopyrrolate/Formoterol Fum40$17,257
LinzessLinaclotide31$16,639
TradjentaLinagliptin17$14,604
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,216
SymbicortBudesonide/Formoterol Fumarate43$11,000
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,368
OxycontinOxycodone Hcl12$10,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$861$122,332164 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat$548$82,950111 claims
GSKTrelegy Ellipta, Anoro Ellipta$454$42,98269 claims
AstraZenecaBevespi Aerosphere, Symbicort, Breztri Aerosphere$1,218$38,62599 claims
AbbVieCreon, Linzess$1,273$38,07550 claims
Novo NordiskOzempic$235$33,20725 claims
MerckJanuvia$234$30,03627 claims
Johnson & JohnsonXarelto$870$27,29240 claims
Astellas Pharma US IncMyrbetriq$116$9,79715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 family medicine providers in Rhode Island.

Other family medicine in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →